Mielim Y Mas

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of cough that may occur with the common cold or as a result of inhaled irritants.

Dosage and Administration

The medication should be shaken well immediately before use to ensure proper mixing of the formulation.

For adults and children aged 12 years and older, the recommended dosage is 10 ml (2 teaspoons) administered every 6 to 8 hours. It is important to note that the total number of doses should not exceed 4 in any 24-hour period.

For children aged 6 to under 12 years, the recommended dosage is 5 ml (1 teaspoon) every 6 to 8 hours, adhering to the same maximum limit of 4 doses within a 24-hour timeframe.

For children under 6 years of age, it is advised to consult a healthcare professional for appropriate dosing recommendations.

Contraindications

Use of this product is contraindicated in the following situations:

Patients with persistent or chronic cough, such as that associated with smoking, asthma, or emphysema, or if the cough is accompanied by excessive phlegm (mucus), unless directed by a healthcare professional. This is due to the potential for masking underlying conditions that require medical evaluation.

The product should not be used in conjunction with prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, use is contraindicated for 2 weeks following the discontinuation of an MAOI due to the risk of serious drug interactions.

If there is uncertainty regarding whether a prescription drug contains an MAOI, it is essential to consult a healthcare professional, such as a doctor or pharmacist, before using this product.

Warnings and Precautions

A persistent cough may indicate an underlying serious condition. Healthcare professionals should advise patients to seek medical consultation if a cough persists for more than one week, recurs frequently, or is accompanied by additional symptoms such as fever, rash, or a persistent headache.

In the event that a cough persists beyond one week, recurs, or is associated with fever, rash, or persistent headache, it is imperative to discontinue use and consult a healthcare provider for further evaluation.

In cases of accidental overdose, immediate medical assistance should be sought. Patients or caregivers are encouraged to contact the Poison Control Center without delay to ensure appropriate management and care.

Side Effects

Patients should be aware that a persistent cough may indicate a serious underlying condition. If a cough persists for more than one week, recurs, or is accompanied by additional symptoms such as fever, rash, or a persistent headache, it is essential to consult a healthcare professional for further evaluation. This warning highlights the importance of monitoring respiratory symptoms and seeking timely medical advice to address potential complications.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Mielim Y Mas (dextromethorphan). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 to under 12 years may be administered a dosage of 5 ml (1 teaspoon) every 6 to 8 hours. For children under 6 years of age, it is advised to consult a doctor before administration.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate assessment of the patient's condition is crucial. Recommended actions include:

1. Assessment: Conduct a thorough evaluation of the patient's vital signs and clinical status. Monitor for any signs of toxicity or adverse reactions.

2. Supportive Care: Initiate supportive measures as necessary, which may include airway management, oxygen supplementation, intravenous fluids, and monitoring in a controlled environment.

3. Decontamination: If the overdose is recent and the patient is alert, consider activated charcoal administration to limit further absorption of the substance. However, this should be avoided in cases of altered mental status or risk of aspiration.

4. Specific Antidotes: If applicable, administer specific antidotes as indicated for the substance involved in the overdose. Familiarity with the appropriate antidotes and their administration protocols is essential.

5. Consultation: Engage with a poison control center or toxicology expert for guidance on management strategies tailored to the specific overdose scenario.

6. Documentation: Ensure thorough documentation of the incident, including the substance involved, estimated dose, time of ingestion, and all interventions performed.

In summary, while no specific overdosage information is provided, healthcare professionals should be prepared to act swiftly and effectively in managing potential overdose situations, utilizing established protocols and resources to ensure optimal patient outcomes.

Nonclinical Toxicology

No relevant information was found regarding teratogenic effects, non-teratogenic effects, or any aspects of nonclinical toxicology. Additionally, there are no findings related to animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is crucial to emphasize the importance of safety in the home environment, particularly for households with young children.

In the event of an accidental overdose, healthcare providers should instruct patients to seek medical help immediately or contact the Poison Control Center. Patients should be made aware of the signs of overdose and the urgency of obtaining assistance to ensure their safety and well-being.

Storage and Handling

The product is supplied in a configuration that requires careful handling. It is essential to shake well immediately before use to ensure proper mixing and efficacy.

For optimal storage, the product should be kept at controlled room temperature, away from direct sunlight and moisture. Specific container requirements have not been detailed; however, it is advisable to store the product in its original packaging to maintain stability and integrity. Special handling needs include ensuring that the product is not exposed to extreme temperatures or conditions that may compromise its quality.

Additional Clinical Information

Patients aged 12 years and older are advised to take 10 ml (2 teaspoons) every 6 to 8 hours, while those between 6 to under 12 years should take 5 ml (1 teaspoon) every 6 to 8 hours. For children under 6 years of age, consultation with a doctor is recommended prior to administration.

Clinicians should counsel patients to seek advice from a health professional if they are pregnant or breastfeeding. In the event of an accidental overdose, patients should obtain medical assistance or contact the Poison Control Center immediately. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Mielim Y Mas, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)